CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Tóm tắt
The SDF-1 receptor CXCR4 has been associated with early metastasis and poorer prognosis in breast cancers, especially the most aggressive triple-negative subtype. In line with previous reports, we found that tumoral CXCR4 expression in patients with locally advanced breast cancer was associated with increased metastases and rapid tumor progression. Moreover, high CXCR4 expression identified a group of bone marrow–disseminated tumor cells (DTC)-negative patients at high risk for metastasis and death. The protein epitope mimetic (PEM) POL5551, a novel CXCR4 antagonist, inhibited binding of SDF-1 to CXCR4, had no direct effects on tumor cell viability, but reduced migration of breast cancer cells in vitro. In two orthotopic models of triple-negative breast cancer, POL5551 had little inhibitory effect on primary tumor growth, but significantly reduced distant metastasis. When combined with eribulin, a chemotherapeutic microtubule inhibitor, POL5551 additively reduced metastasis and prolonged survival in mice after resection of the primary tumor compared with single-agent eribulin. Hypothesizing that POL5551 may mobilize tumor cells from their microenvironment and sensitize them to chemotherapy, we used a “chemotherapy framing” dosing strategy. When administered shortly before and after eribulin treatment, three doses of POL5551 with eribulin reduced bone and liver tumor burden more effectively than chemotherapy alone. These data suggest that sequenced administration of CXCR4 antagonists with cytotoxic chemotherapy synergize to reduce distant metastases. Mol Cancer Ther; 14(11); 2473–85. ©2015 AACR.
Từ khóa
Tài liệu tham khảo
Teicher, 2010, CXCL12 (SDF-1)/CXCR4 pathway in cancer, Clin Cancer Res, 16, 2927, 10.1158/1078-0432.CCR-09-2329
Dar, 2006, Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice, Exp Hematol, 34, 967, 10.1016/j.exphem.2006.04.002
Ma, 1998, Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice, Proc Natl Acad Sci U S A, 95, 9448, 10.1073/pnas.95.16.9448
Nagasawa, 1996, Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1, Nature, 382, 635, 10.1038/382635a0
Ara, 2003, Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny, Immunity, 19, 257, 10.1016/S1074-7613(03)00201-2
Liles, 2003, Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist, Blood, 102, 2728, 10.1182/blood-2003-02-0663
Li, 2006, Normal stem cells and cancer stem cells: the niche matters, Cancer Res, 66, 4553, 10.1158/0008-5472.CAN-05-3986
Shiozawa, 2011, Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow, J Clin Invest, 121, 1298, 10.1172/JCI43414
Chatterjee, 2014, The intricate role of CXCR4 in cancer, Adv Cancer Res, 124, 31, 10.1016/B978-0-12-411638-2.00002-1
Meads, 2008, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance, Clin Cancer Res, 14, 2519, 10.1158/1078-0432.CCR-07-2223
Castells, 2012, Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death, Int J Mol Sci, 13, 9545, 10.3390/ijms13089545
Zhang, 2013, Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma, Cell, 154, 1060, 10.1016/j.cell.2013.07.036
Azab, 2009, CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy, Blood, 113, 4341, 10.1182/blood-2008-10-186668
Domanska, 2013, A review on CXCR4/CXCL12 axis in oncology: no place to hide, Eur J Cancer, 49, 219, 10.1016/j.ejca.2012.05.005
Karshovska, 2008, A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury, J Thromb Haemost, 6, 1812, 10.1111/j.1538-7836.2008.03086.x
Hu, 2013, CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair, J Surg Res, 183, 427, 10.1016/j.jss.2013.01.019
Chu, 2010, High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome, J Surg Res, 159, 689, 10.1016/j.jss.2008.09.020
Braun, 2005, A pooled analysis of bone marrow micrometastasis in breast cancer, N Engl J Med, 353, 793, 10.1056/NEJMoa050434
Chen, 2013, Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer, Curr Mol Med, 13, 410
Zhang, 2012, The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer, Ultrastruct Pathol, 36, 381, 10.3109/01913123.2012.728687
Peled, 2012, Development of novel CXCR4-based therapeutics, Expert Opin Invest Drugs, 21, 341, 10.1517/13543784.2012.656197
Domanska, 2014, CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model, Clin Exp Metastasis, 31, 829, 10.1007/s10585-014-9673-2
Kim, 2008, Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases, Clin Exp Metastasis, 25, 201, 10.1007/s10585-007-9133-3
D'Alterio, 2012, Inhibition of stromal CXCR4 impairs development of lung metastases, Cancer Immunol Immunother, 61, 1713, 10.1007/s00262-012-1223-7
Robinson, 2008, The design, structures and therapeutic potential of protein epitope mimetics, Drug Discov Today, 13, 944, 10.1016/j.drudis.2008.07.008
Karpova, 2013, The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor, Leukemia, 27, 2322, 10.1038/leu.2013.266
Hamesch, 2012, The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation, Thromb Haemost, 107, 356, 10.1160/TH11-07-0453
Barone, 2014, Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma, Oncotarget, 5, 9811, 10.18632/oncotarget.2443
Aft, 2010, Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial, Lancet Oncol, 11, 421, 10.1016/S1470-2045(10)70054-1
Lin, 2010, A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy, Breast Cancer Res Treat, 123, 691, 10.1007/s10549-009-0664-y
Watson, 2007, Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients, Clin Cancer Res, 13, 5001, 10.1158/1078-0432.CCR-07-0024
Budczies, 2012, Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization, PLoS ONE, 7, e51862, 10.1371/journal.pone.0051862
Smith, 2004, CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res, 64, 8604, 10.1158/0008-5472.CAN-04-1844
Guise, 1996, Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis, J Clin Invest, 98, 1544, 10.1172/JCI118947
Luker, 2012, In vivo imaging of ligand receptor binding with Gaussia luciferase complementation, Nat Med, 18, 172, 10.1038/nm.2590
DeMarco, 2006, Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles, Bioorg Med Chem, 14, 8396, 10.1016/j.bmc.2006.09.003
Heller, 2012, Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment, Cancer Res, 72, 897, 10.1158/0008-5472.CAN-11-2681
Su, 2012, The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling, J Clin Invest, 122, 3579, 10.1172/JCI38576
Kochetkova, 2009, Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells, Cell Death Differ, 16, 664, 10.1038/cdd.2008.190
Uluckan, 2009, CD47 regulates bone mass and tumor metastasis to bone, Cancer Res, 69, 3196, 10.1158/0008-5472.CAN-08-3358
Andre, 2009, CXCR4 expression in early breast cancer and risk of distant recurrence, Oncologist, 14, 1182, 10.1634/theoncologist.2009-0161
Hung, 2014, High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases, Tumour Biol, 35, 1581, 10.1007/s13277-013-1218-9
Fehm, 2006, A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation, Cancer, 107, 885, 10.1002/cncr.22076
Gnant, 2011, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, Lancet Oncol, 12, 631, 10.1016/S1470-2045(11)70122-X
Ben-Aharon, 2013, Bisphosphonates in the adjuvant setting of breast cancer therapy–effect on survival: a systematic review and meta-analysis, PLoS ONE, 8, e70044, 10.1371/journal.pone.0070044
Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285
Rhodes, 2011, Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer, Cancer Res, 71, 603, 10.1158/0008-5472.CAN-10-3185
Burns, 2006, A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development, J Exp Med, 203, 2201, 10.1084/jem.20052144
Kirui, 2010, Gbetagamma signaling promotes breast cancer cell migration and invasion, J Pharmacol Exp Ther, 333, 393, 10.1124/jpet.109.164814
Twelves, 2014, Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies, Breast Cancer Res Treat, 148, 553, 10.1007/s10549-014-3144-y
Cortes, 2011, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6
Cortes, 2010, Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine, J Clin Oncol, 28, 3922, 10.1200/JCO.2009.25.8467
Salazar, 2014, The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation, Mol Cancer, 13, 198, 10.1186/1476-4598-13-198
Hernandez, 2011, Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis, Breast Cancer Res, 13, R128, 10.1186/bcr3074
Hattermann, 2010, The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects, Cancer Res, 70, 3299, 10.1158/0008-5472.CAN-09-3642
Muller, 2001, Involvement of chemokine receptors in breast cancer metastasis, Nature, 410, 50, 10.1038/35065016
Kang, 2003, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, 3, 537, 10.1016/S1535-6108(03)00132-6
Hirbe, 2007, Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone, Proc Natl Acad Sci U S A, 104, 14062, 10.1073/pnas.0705203104
Bauer, 2007, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, Cancer, 109, 1721, 10.1002/cncr.22618
Haffty, 2006, Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer, J Clin Oncol, 24, 5652, 10.1200/JCO.2006.06.5664
Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, 26, 1275, 10.1200/JCO.2007.14.4147
Donoghue, 2012, Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a “physician's choice” control arm in a randomized approval trial, Clin Cancer Res, 18, 1496, 10.1158/1078-0432.CCR-11-2149
Domanska, 2012, CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy, Neoplasia, 14, 709, 10.1593/neo.12324